Regencell Bioscience Holdings Limited (RGC)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$7.41−2.86%as of Oct 9, 2026, 12:08 PM ET
- Market cap
- $3.7B
- 52-week range
- $4.51 – $69.00
- 52-week change
- −54.61%
- EPS (trailing)
- −$0.02
- Next earnings
- Oct 28, 2026
Fiscal year to Jun 2026
- Net income
- −$11.7M
- Diluted EPS
- −$2.37
From the company’s annual report on SEC EDGAR.
About Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Headquarters: Causeway Bay, Hong Kong · regencellbioscience.com